The Use Of Peripheral Blood Stem Cells For Allogeneic Transplantation
- Determine the efficacy and safety of allogeneic peripheral blood stem cell
transplantation in achieving engraftment in patients with hematologic malignancy.
- Determine the hematopoietic recovery, incidence of chemoradiotherapeutic toxicity,
relapse, graft-versus-host disease, and survival of patients treated with this regimen.
OUTLINE: Patients receive a preparative chemoradiotherapeutic regimen and graft-versus-host
disease prophylaxis prior to transplantation. Patients undergo allogeneic peripheral blood
stem cell transplantation on day 0.
Patients are followed every 1-2 weeks for 6 months and at 9, 12, 24, and 36 months.
PROJECTED ACCRUAL: A total of 62 patients will be accrued for this study within 4 years.
Primary Purpose: Treatment
David G. Savage, MD
Herbert Irving Comprehensive Cancer Center
|Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center||New York, New York 10032|